UNSPSC 51141546: Ameltolide

This classification denotes an anticonvulsant agent with the molecular formula C15H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F83240ZOVE, chemically known as 4-amino-n-(2,6-dimethylphenyl)benzamide but generally known as ameltolide, which bears US NIH Compound Identifier 13086. European Medicines Agency schedules Ameltolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05408MIG.

UNSPSC 51141546 Ameltolide is a Commodity code that in recent state and local practice encompasses pharmaceutical procurement, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work involves establishing supply contracts with manufacturers and wholesalers, negotiating pricing structures, ensuring FDA compliance and cGMP certification, managing quarterly or ongoing deliveries to government health facilities, and often requiring vendors to work through authorized distribution channels. Issuing bodies typically demand detailed product information including National Drug Codes and packaging specifications, compliance certifications including the Drug Supply Chain Security Act, comprehensive insurance coverage, and adherence to electronic procurement and data interchange systems.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory phase preceding formal competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating state and local government facilities, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. MMCAP evaluations weight price competitiveness at 75 percent, with administrative compliance, EDI capability, and fixed-pricing transparency comprising the remainder.